Skip to main content
. 2017 Sep 12;23(2):111–121. doi: 10.1177/2472555217729790

Figure 2.

Figure 2.

Potency and maximum efficacy improvements during optimization of PTI-CH. (A) Comparison of relative potency and activity of original hit compound PTI-CA with the optimized compound PTI-CH in the original CFBE41-YFP F508del–cystic fibrosis transmembrane conductance regulator (CFTR) functional assay. (B) Comparison of the relative potency and activity of PTI-CA with PTI-CH in the F508del/F508del human bronchial epithelial (HBE) CFTR functional assay. YFP, yellow fluorescent protein.